Loading
Neurotransmitter Receptor Influence on Behavior / Treatment of Major Depression · Journal article
L Encéphale · August 1, 2026
Raises a question worth testing. It does not answer one.
This is a perspective article proposing 5-HT4 receptor agonism, exemplified by prucalopride, as a potential therapeutic target for mood disorders based on preclinical pharmacology and mechanistic reasoning. The evidence presented is preliminary and hypothesis-generating; no clinical efficacy data in depression or anxiety are reported in this source.
Journal article. Conceptual; patients with major depressive disorder, anxiety, or mood disorders are the proposed target population, but no actual enrolled cohort is described..
Preclinical studies demonstrate that 5-HT4 receptor agonists produce rapid antidepressant- and anxiolytic-like effects, accompanied by early neuroplastic adaptations. Prucalopride is a highly selective 5-HT4 receptor agonist already approved for chronic idiopathic constipation. Converging evidence from animal models, experimental human studies, and epidemiological analyses suggests prucalopride may modulate mood-related neural circuits and cognitive processes.
Prucalopride's psychiatric safety and tolerability in depressed or anxious patients are not addressed.
Clinicians should regard this as an early-stage translational hypothesis rather than evidence for clinical use. Prucalopride remains approved only for constipation; any psychiatric application would require controlled clinical trials.
This is a perspective article proposing a mechanistic hypothesis about 5-HT4 receptor agonists in mood disorders, supported by preclinical evidence and epidemiological suggestion, but lacking clinical trial data demonstrating efficacy in humans with depression or anxiety.
Clinicians should regard this as an early-stage translational hypothesis rather than evidence for clinical use. Prucalopride remains approved only for constipation; any psychiatric application would require controlled clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Major depressive disorder remains a leading cause of disability worldwide, and current antidepressant treatments are limited by a delayed onset of action, modest remission rates, and residual symptoms. Emerging evidence suggests that selective targeting of specific serotonergic receptors may offer faster and more precise therapeutic strategies. Among these targets, the serotonin type 4 (5-HT 4 ) receptor has gained increasing attention due to its involvement in corticolimbic circuits regulating mood, cognition, and stress responses. Preclinical studies demonstrate that 5-HT 4 receptor agonists produce rapid antidepressant- and anxiolytic-like effects, accompanied by early neuroplastic adaptations. Prucalopride, a highly selective 5-HT 4 receptor agonist approved for chronic idiopathic constipation, has recently emerged as a promising candidate for drug repurposing in psychiatry. Converging evidence from animal models, experimental human studies, and epidemiological analyses suggest that prucalopride may modulate mood-related neural circuits and cognitive processes. This perspective discusses the translational potential of 5-HT 4 receptor agonism as a novel therapeutic avenue for mood disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.